leadf
logo-loader
viewPediapharm

Full interview: Medexus Pharmaceuticals unveils jump in 1Q revenue, increased earnings

Medexus Pharmaceuticals Inc (CVE:KMDP) (OTCMKTS:PDDPF) CEO Ken d'Entremont stopped by Proactive New York to talk about the Canadian-based biopharma's fiscal first-quarter results, which showed a year-over-year jump in revenue jump to C$16.1 million, and positive EBITDA of C$0.5 million.

d'Entremont says while the increase in numbers stems from the acquisitions of Pediapharm Inc, Medexus Inc and Medac Pharma Inc,, strong organic growth through its lead products Rasuvo, Metoject, and Rupall contributed, as well.

Quick facts: Pediapharm

Price: - -

TSX-V:PDP
Market: TSX-V
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Chimeric Therapeutics new very experienced COO has bold vision to move CAR T...

Chimeric Therapeutics (ASX: CHM) newly appointed COO Jennifer Chow joined Steve Darling from Proactive to talk about her vision for the company. Chow talks about her background working in cell therapy and how Chimeric hopes to be a big player in it. Chow also told Proactive about their lead...

3 hours, 29 minutes ago

2 min read